key: cord-0747259-ngie2kzz authors: Maltezou, Helena C.; Krumbholz, Bettina; Mavrouli, Maria; Tseroni, Maria; Gamaletsou, Maria N.; Botsa, Evanthia; Anastassopoulou, Cleo; Gikas, Aristofanis; Fournarakou, Evanthia; Kavieri, Maria; Koureli, Aikaterini; Mandilara, Dionysia; Marinopoulou, Aikaterini; Theodorikakou, Argyro; Tsiahris, Panagiotis; Zarzali, Anastasia; Pournaras, Spyridon; Lourida, Athanasia; Elefsiniotis, Ioannis; Vrioni, Georgia; Sipsas, Nikolaos V.; Tsakris, Athanasios title: A study of the evolution of the third COVID‐19 pandemic wave in the Athens metropolitan area, Greece, through two cross‐sectional seroepidemiological surveys: March, June 2021 date: 2021-12-04 journal: J Med Virol DOI: 10.1002/jmv.27465 sha: 7be201712a88715abc3c192d9acd4d2d673370b1 doc_id: 747259 cord_uid: ngie2kzz We studied the third coronavirus disease 2019 (COVID‐19) pandemic wave in Athens metropolitan area (3 738 901 inhabitants) through two seroepidemiological surveys. Persons presenting in 12 healthcare facilities across Athens in March and June 2021 were studied (764 and 901, respectively). Immunoglobulin G antibodies against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) spike protein were measured by a chemiluminescent microparticle immunoassay. In March the seroprevalence rate was 11.6%, meaning that 435 208 residents of Athens had evidence of immunity. The respective values in June were 55.7% and 2 082 568 residents. The highest seroprevalence rates attributed to SARS‐CoV‐2 infection were recorded in persons <18 years (16.3% in March and 31.6% in June), while immunity was mainly vaccine‐induced in persons 18–64 years and >65 years. Infection‐attributed immunity also increased in older‐age groups. Wide ranges in seroprevalence rates were noted across areas in March and June. The highest seroprevalence rates were recorded in Piraeus (47.2%) and West Attica (37.5%). However, the highest increase (>5 times) occurred in Piraeus and the South Section of Athens, which are among the most densely populated areas in Athens. In both study periods, history of COVID‐19 or febrile episode, and having a cohabitant with COVID‐19 were associated with increased risk for seropositivity among unvaccinated persons (p values <0.001 for all). Residing in Piraeus, the South Section or West Attica was associated with increased risk for seropositivity in June (p values <0.001). Wide heterogeneity in seroprevalence rates was found across areas in Athens, which is mainly attributed to population density. The impact of population mobility and socioeconomic status should be explored. Almost 2 years after the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the declaration of the coronavirus disease 2019 (COVID-19) pandemic, humanity continues to face its considerable health, societal, and economic consequences. 1 As of November 9, 2021, more than 249 million laboratory-confirmed cases and more than 5 million deaths have been reported globally. 2 Pandemics are often heterogeneous in terms of spatial and temporal evolution and wide differences may occur between and within populations. [3] [4] [5] [6] These differences are mainly driven by varying levels of population immunity in the context of consecutive pandemic waves, but also by population density, human mobility networks, and the mixture and magnitude of implemented countermeasures which may shift the characteristics of the pandemic. [3] [4] [5] [6] Mass vaccination is the key countermeasure to limit COVID-19 associated morbidity and mortality and to speed the return to normality. 7 The first COVID-19 vaccines were developed and granted emergency use authorization within less than a year after the declaration of the pandemic. 8 Currently, there are several COVID-19 vaccines in use globally. 8 In Greece, the first COVID-19 case was detected on February 26, 2020. 9 Following a small wave in March-May 2020, Greece experienced two large waves in September-December 2020 and February-June 2021, respectively. 10 Overall, as of November 9, 2021, 801 208 cases and 16 414 deaths have been notified in Greece. 10 Yet, there are many more infections than those officially documented, as many infected persons remain asymptomatic or develop mild symptoms and therefore go unnoticed. 9, 11, 12 Seroprevalence studies can capture past infections in a population at a specific time, including asymptomatic or mildly symptomatic infections. [13] [14] [15] These studies can also detect vaccine-induced immunity and, therefore, can be used to estimate the overall immunity levels of a population. However, to the best of our knowledge, the overwhelming majority of seroprevalence surveys worldwide concerned either the first pandemic wave or special population groups such as healthcare personnel, while on several occasions they relied on residual clinical specimens. 11, 16, 17 Although it is highly likely that SARS-CoV-2 will become endemic in the coming years, there are uncertainties regarding transition dynamics from COVID-19 pandemic to endemicity, the emergence of new variants, and the expected concomitant pressure of seasonal influenza on healthcare services. 18, 19 Regarding Greece, this is critical given that as of November 11, 2021, 62% of the general population is fully vaccinated, rendering this country 23rd in the ranking of European countries. 20 In that respect, we conducted a prospective, two time-point seroepidemiological study in the Athens metropolitan area where one-third of the population of Greece resides. Our objective was to study the evolution of the third COVID-19 pandemic wave and factors influencing the risk for SARS-CoV-2 seropositivity. The resident population in the Athens metropolitan area amounted to 3 738 901 inhabitants (2011 census). 21 With a 15% expected seroprevalence rate against SARS-CoV-2, it was estimated that a sample of 625 persons was required for each cross-sectional seroepidemiological survey for a 2.7% margin of error, 90% power, and 95% confidence interval (CI) (power analysis). 2.2 | Enrolment of participants, data collection, and sera sampling The COVID-19 vaccination campaign started on December 28, 2020. Healthcare personnel were prioritized, followed by the elderly (>80 years and >70-79 years), persons with co-morbidities, and younger age groups. The following vaccines were used: Comirnaty In March 2021, 89 persons tested seropositive against SARS-CoV-2, therefore the overall seroprevalence rate was 11.6% (CI: 9.5%-14.1%). This implies that at that time approximately 435 208 residents of the Athens metropolitan area had serologic evidence of immunity against SARS-CoV-2. In June 2021, 502 persons tested seropositive against SARS-CoV-2. Persons <18 years old had the highest seroprevalence rates attributed to natural SARS-CoV-2 infection in both studied periods (16.3% in March and 31.6% in June) ( Table 3 ). In contrast, serologically proven immunity against SARS-CoV-2 was mainly vaccine-induced in persons 18-64 years and ≥65 years (Tables 2 and 3 ). Nevertheless, seroprevalence attributed to natural SARS-CoV-2 infection also increased during the third pandemic wave in older-age groups (Table 3) . Wide ranges in seroprevalence rates against SARS-CoV-2 attributed to natural infection were noted across studied areas ( We conducted a two-point seroprevalence survey in March and June 2021 to study the evolution of the third COVID-19 pandemic wave in the Athens metropolitan area, which is mostly urban, with significant variations in population density and socioeconomic status of residents. To the best of our knowledge, this is among the few prospectively conducted seroepidemiological surveys not focusing on risk groups, and the only one conducted in the third pandemic wave, after the implementation of mass COVID-19 vaccination programs. Seroprevalence surveys at the regional level can yield valuable insights to guide future intervention policies but also prepare the healthcare system. This is imperative given the emergence of new variants, the upcoming influenza season, and the suboptimal COVID-19 vaccine uptake rates in Greece, which can fuel additional waves of severe cases, hospitalizations, and deaths. 22 We estimated that the seroprevalence rate against SARS-CoV-2 increased sharply from 11.6% in March 2021 to 55.7% in June 2021. In particular, we estimated that approximately 435 208 residents in Athens had serologic evidence of immunity in March. This number was raised fivefold (to 2 082 568 residents) within a period of 3 months. This evolution is mainly attributed to the fast pace of the national vaccination program, which should be maintained until the vast majority of the population is vaccinated. High (31.5%) seroprevalence rates after the first pandemic wave were detected in the urban area of Chelsea, Massachusetts. 23 In contrast, negligible seroprevalence rates (<0.5%) against SARS-CoV-2 were estimated after the first pandemic wave in Greece, which is attributed to the early implementation of nationwide lockdown. 24 (range: 33.4%-100%). 28 High attack rates (up to 75%) within families were also found by others. 29, 30 Finally, a history of febrile episode up to 9 months before testing was also predictive of seropositivity, as also shown in other studies. 31, 32 Similarly with past pandemics and the ongoing COVID-19 pandemic, [3] [4] [5] [6] 33, 34 wide differences in seroprevalence rates against SARS-CoV-2 across areas were found in our study. However, we found no statistical significance between the two study periods, which is explained by the rather small number of tested persons per Our study has several strengths. We enrolled a large number of asymptomatic persons early in the third pandemic wave and at the end, which allowed us to study in detail the evolution of immunity against SARS-CoV-2. In addition, a clear strength is the fact that we tested persons from all areas of the Athens metropolitan area and of all age groups. A potential limitation is the fact that persons seeking healthcare may not represent the general population. Yet, epidemiological data and serum specimens were collected concomitantly and prospectively, instead of testing residual clinical specimens. In conclusion, our study provides insight into the evolution of the third COVID-19 pandemic wave in the Athens metropolitan area. Our study showed that the seroprevalence of IgG antibodies against SARS-CoV-2 increased sharply during the 3-month period. This evolution is mainly attributed to the fast pace of the national vaccination program, indicating that it should be maintained until the vast majority of the population is vaccinated. Despite the implemented strict lockdown policies, SARS-CoV-2 circulated widely and infected significant portions across all age groups, and particularly among persons <18 years old. Wide differences in seroprevalence rates were noted among regions. Beyond population density, it is likely that human mobility and connectivity also accounted for the spatial heterogeneity in seroprevalence rates. The role of socioeconomic status should also be explored. Overall, our study can inform policymakers to plan future public health interventions in light of the expected emergence of novel variants of concern, the upcoming influenza season, and the suboptimal vaccination coverage rates against COVID-19 in Greece. Aikaterini Dentaki (Primary Healthcare Center Primary Healthcare Center of Neos Kosmos 5120 published online ahead of print Apr 2 2. Weekly epidemiological update on COVID-19 -5 The signature features of influenza pandemics-implications for policy The 1918-1919 influenza pandemic in England and Wales: spatial patterns in transmissibility and mortality impact Epidemiologic characterization of the 1918 influenza pandemic summer wave in Copenhagen: implications for pandemic control strategies Seroepidemiological study of pandemic influenza H1N1 following the 2009-2010 wave in Greece Virus, vaccines, and variants Speed, evidence, and safety characteristics of vaccine approvals by the US Food and Drug Administration Coronavirus disease 2019 pandemic in Greece National Public Health Organization. Daily reports of epidemiological surveillance of SARS-CoV-2 infections (COVID-19 Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study Prevalence of SARS-CoV-2 IgG antibodies in an area of northeastern Italy with a high incidence of COVID-19 cases: a population-based study Population-based estimates of SARS-CoV-2 seroprevalence in Houston, TX as of Seroprevalence of SARS-CoV-2 antibodies in the US adult asymptomatic population as of SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based crosssectional study SARS-CoV-2 antibody seroprevalence after the first wave among workers at at community healthcare system in the Greater Boston area Seroprevalence of SARS-CoV-2-specific antibodies in Sydney after the first epidemic wave of 2020 Influenza immunization and COVID-19 Immunological characteristics govern the transition of COVID-19 to endemicity Data. Coronavirus (COVID-19) vaccinations, available at Hellenic Statistical Authority. 2011 population census Implications of suboptimal COVID-19 vaccination coverage in Florida and Texas High seroprevalence of anti-SARS-CoV-2 antibodies in Repeated leftover serosurvey of SARS-CoV-2 IgG antibodies COVID-19 government response tracker Analyzing the effectiveness of COVID-19 lockdown policies using the time-dependent reproduction number and the regression discontinuity framework: comparison between countries Assessment of seroprevalence of SARS-CoV-2 and risk factors associated with COVID-19 infection among outpatients in Virginia Transmission dynamics of SARS-CoV-2 within families with children in Greece: a study of 23 clusters Transmission potential of asymptomatic and paucisymptomatic severe acute respiratory syndrome coronavirus 2 infections: a 3-family cluster study in China Clinical and epidemiological features of a family cluster of symptomatic and asymptomatic severe acute respiratory syndrome coronavirus 2 infection Nationwide seroprevalence of SARS-CoV-2 and identification of risk factors in the general population of the Netherlands during the first epidemic wave Prevalence of antibodies to SARS-CoV-2 in Italian adults and associated risk factors Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis Higher SARS-CoV-2 seroprevalence in workers with lower socioeconomic status in Cape Town, South Africa A study of the evolution of the third COVID-19 pandemic wave in the Athens metropolitan area, Greece, through two cross-sectional seroepidemiological surveys: March We thank the healthcare personnel of the participating healthcare facilities for their assistance in collecting data and blood sampling.We also thank Anastasia Tedoma for technical assistance. The opinions presented in this article are those of the authors, and do not necessarily represent those of their institutions. Funding information is not available. The authors declare that there are no conflict of interests. The data that support the findings of this study are available from the corresponding author upon reasonable request.